MDMA Therapy Rollout
The FDA is nearing a pivotal decision on the licensing of MDMA as a treatment for PTSD, with promising phase three trial results showing a 67% remission rate. While the timeline for rollout is optimistic, questions remain about who will provide this therapy and how to ensure the purity of the substance. As organizations like Maps prepare to potentially step in, the complexities of becoming a pharmaceutical provider loom large.In this clip
From this podcast
Huberman Lab
Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health | Huberman Lab Podcast
Related Questions
When will psychedelic therapy be widely available after the episode Rick Doblin: Psychedelics | Lex Fridman Podcast #202 and the clip Psychedelics and Access discussing MDMA for PTSD?
How effective is MDMA therapy for PTSD as discussed in the Huberman Lab Podcast episode 81: Michael Pollan | A Renaissance in the Forbidden Science of Psychedelics and the clip Healing with MDMA?